Blood Testing Questions Routine Marrow Checks in CML - EMJ

This site is intended for healthcare professionals

Blood Testing Questions Routine Marrow Checks in CML

Author:

Key Summary:

  • Blood and bone marrow cytogenetic findings matched in all 12 paired cases.
  • Marrow findings did not change initial treatment or risk classification in the paired cohort.
  • The small retrospective study supports prospective research before routine practice changes.
person having lumbar puncture

PERIPHERAL BLOOD testing could provide sufficient cytogenetic information for some patients newly diagnosed with typical chronic-phase chronic myeloid leukaemia (CML), a small retrospective study suggests.

Researchers at Mayo Clinic, Rochester, Minnesota, USA, found complete agreement between paired peripheral blood and bone marrow cytogenetic results. Bone marrow findings did not change initial management or risk classification in any paired case. However, the findings remain preliminary and do not establish that routine marrow examination can safely be omitted.

Comparing Blood and Marrow Testing

The diagnostic assessment of CML confirms the BCR::ABL1 fusion, establishes disease phase, and identifies chromosomal abnormalities that may influence prognosis. Bone marrow examination also provides information about marrow morphology and other underlying pathology.

The study included 17 patients with chronic-phase CML, with a median age of 69 years. Twelve underwent both peripheral blood and bone marrow karyotyping within 8 weeks of each other at diagnosis. The remaining five were assessed using peripheral blood testing alone.

Researchers compared chromosome findings at the level of individual abnormal cell populations and assessed whether marrow results affected risk stratification or treatment selection. Risk was assessed using the EUTOS long-term survival score.

Matching Cytogenetic Findings

Peripheral blood and bone marrow cytogenetic findings were concordant in all 12 paired cases. No marrow result changed the patient’s risk category or initial treatment.

Among the five patients assessed using peripheral blood alone, all could be risk-stratified and started imatinib without complication. At 1 year, four had achieved a major molecular response, while one had achieved a complete cytogenetic response.

These observations suggest that adequate peripheral blood cytogenetics may provide the chromosome information needed for initial assessment in selected patients. However, the blood-only group was small and was not randomly assigned, preventing firm comparisons between diagnostic approaches.

Further Validation Needed

The authors suggest that a comprehensive blood-based assessment could be sufficient for many patients with otherwise typical chronic-phase CML. Reducing routine marrow procedures could lessen pain, anxiety, and demands on healthcare resources.

Nevertheless, marrow examination retains value when advanced-phase disease is suspected, blood cytogenetics are inadequate, or unexplained cytopenias or other clinical findings suggest an additional marrow disorder.

The study’s small size, retrospective design, and single-centre setting limit how widely its results can be applied. Rare findings confined to the marrow, including focal blast collections or significant fibrosis, could also be missed in a larger blood-only population.

The researchers therefore call for prospective validation of a predefined blood-based diagnostic pathway, with paired marrow assessment and independent review of management decisions. Their findings support further investigation, while existing diagnostic recommendations continue to include bone marrow assessment.

Reference

Al Kurnas M et al. Is bone marrow examination still required at diagnosis of typical chronic-phase chronic myeloid leukemia? Evidence from paired peripheral blood and bone marrow cytogenetics. Am J Hematol. 2026. doi:10.1002/ajh.70555.

 

Featured image: Алексей Доненко on AdobeStock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.